News Square
Global Crypto News · Real-time Aggregation
📚 Deep Analysis
More →GRVT Burns 1.1 Million Tokens as Countdown to Grvt 2.0 Begins
<strong>[PRESS RELEASE – Singapore, Singapore, October 20th, 2026]</strong> <strong>The discretionary buyback represents close to 1% of circulating supply and precedes four planned product milestones culminating in Grvt 2.0.</strong> <a href="https://grvt.io/" rel="nofollow noopener" target="_blank">>Grvt</a>, a self-custodial trading platform built on its own zero-knowledge (ZK) chain, announced that the Foundation’s token issuer has completed its first GRVT token buyback, purchasing and burning 1.1 million GRVT tokens on the open market. The transaction permanently removed close to 1% of GRVT’s circulating supply at the time of purchase. It marks the first of five milestones ahead of the planned launch of Grvt 2.0 at the end of November 2026. <strong>A Discretionary Buyback with On-Chain Verification</strong> The Foundation’s token issuer intends to conduct further buybacks on a monthly basis. Each transaction remains entirely at the issuer’s discretion, with no predetermined purchase amount or guaranteed schedule. Buybacks are executed through an independent execution partner, with purchased tokens transferred to a designated burn address and permanently removed from circulation. The transactions can be independently verified through the <a href="https://grvt.io/exchange/buybacks" rel="nofollow noopener" target="_blank">>public buyback dashboard</a>, which records the number of tokens purchased and burned, the percentage of circulating supply represented, cumulative burns and on-chain transaction hashes. “The GRVT token is an important part of the ecosystem we are building,” said <strong>Hong, co-founder and CEO of Grvt</strong>. “We welcome the issuer’s buybacks as a demonstration of its long-term commitment to the ecosystem and community. Grvt is expanding its products and markets, and the issuer’s buybacks sit alongside that as a supportive mechanism aimed at reducing circulating token supply.” <strong>Grvt Outlines Four Product Milestones</strong> The announcement follows GRVT’s token generation event in July 2026 and precedes a series of planned launches. <strong>Grvt Earn, scheduled for the End of October,</strong> will introduce yield opportunities backed by tokenized assets, with target yields of up to 11%. Potential returns are expected to derive from underlying asset cash flows, including interest, premiums and invoice-related income. Asset-supplying partners will be announced at launch. Target yields are not guaranteed. <strong>Stable Funding Perps, scheduled for November,</strong> will introduce perpetual futures linked to commodities, stocks, foreign exchange and indices. The contracts are planned to carry zero trading fees and use once-daily funding. Grvt aims to list more than 1,000 markets by the end of December 2026. <strong>Yield as Margin, also scheduled for November,</strong> will allow eligible Grvt Earn balances to support trading positions while continuing to accrue yield, subject to applicable product terms
OpenAI Buys Orchestra Bio to Put AI Agents in Charge of Drug Development Grunt Work
OpenAI has bought Orchestra Bio, a San Francisco startup whose AI agents help drug companies keep sprawling development programs on schedule, the ChatGPT maker <a href="https://openai.com/index/openai-to-acquire-orchestra-bio/" target="_blank" rel="nofollow external noopener" class="sc-adb616fe-0 dJryYS">>announced Tuesday</a>. “Our goal is to help scientists make discoveries and manage the work needed to turn them into treatments that reach patients sooner,” OpenAI said in the announcement. Orchestra’s team and platform will be folded into <a href="https://openai.com/rosalind/" target="_blank" rel="nofollow external noopener" class="sc-adb616fe-0 dJryYS">>Rosalind</a>, OpenAI’s family of AI models and tools for biologists and chemists. The financial terms were not disclosed. Getting a new medicine from first idea to U.S. approval takes time—up to 15 years according to OpenAI. Every month shaved off that timeline is a month earlier that a new treatment can reach the people waiting for it, and a month earlier that the company can generate cash. The process is also absurdly expensive: bringing one approved drug to market can cost more than <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12668846/" target="_blank" rel="nofollow external noopener" class="sc-adb616fe-0 dJryYS">>$2.6 billion</a>, and <a href="https://arxiv.org/pdf/2106.05386" target="_blank" class="sc-adb616fe-0 dJryYS" rel="nofollow">fewer than 10%</a> of candidates that enter human testing ever make it to pharmacy shelves. Beyond the science itself, OpenAI says drug teams have to coordinate work across internal departments and outside partners, often relying on systems that don’t talk to each other. Those partners usually include contract research organizations, the outside labs hired to run studies, and contract manufacturers that produce the experimental drug. Orchestra’s AI agents—software that can watch over tasks and flag problems on its own—work out which activities and deadlines take the hit, gather the relevant information and compare ways to respond, while scientists and program leaders make the final call. Founded in the fall of 2022, Orchestra raised its <a href="https://jobs.8vc.com/companies/orchestra/jobs/28818089-senior-software-engineer" target="_blank" rel="nofollow external noopener" class="sc-adb616fe-0 dJryYS">>seed round</a> from Andreessen Horowitz, Definition Capital, Insight Partners, and 8VC, and about $20 million in total, according to <a href="https://www.caplight.com/company/orchestra-bio" target="_blank" class="sc-adb616fe-0 dJryYS" rel="nofollow">Caplight data</a>. The company should not be confused with Orchestra BioMed, an unrelated Nasdaq-listed medical device maker that trades under the ticker OBIO. In April, OpenAI launched <a href="https://decrypt.co/364783/openai-gpt-rosalind-drug-discovery-life-sciences-model" target="_blank" class="sc-adb616fe-0 dJryYS" rel="nofollow">GPT-Rosalind</a>, a model built specifically for biology and dru
The U.S. President's special envoy arrives in Russia today.
According to a report by Russian news agency TASS, U.S. Presidential Special Envoy Witkoff arrived in St. Petersburg, Russia today. A day earlier, Witkoff held a meeting with Ukrainian President Zelensky in Oslo, Norway, which was also attended by several European leaders. The talks were aimed at formulating a peace plan that could be submitted to the Russian side for discussion. According to information released by Norwegian Prime Minister Støre, Witkoff hopes to meet with Russian President Putin after arriving in Russia and to brief the Russian side on the content of the Oslo talks.
Upbit suspends GRAM deposits and withdrawals; trading remains unaffected during maintenance.
According to CoinWorld news, Upbit announced that due to maintenance of the GRAM wallet on The Open Network (TON), the platform has suspended GRAM deposit and withdrawal services starting from the announcement on October 21, 2026, with the resumption time to be determined and further notice to follow. During the maintenance period, GRAM trading will not be affected.
BNB Standard will hold a Nasdaq bell-ringing ceremony on October 26.
According to CoinWorld news, Nasdaq-listed company BNB Standard has announced that it will ring the Nasdaq opening bell on October 26 to celebrate the company's rebranding and the appointment of its new management team. The company's CEO will attend the event together with board members, the management team, investors, and ecosystem partners.
The 4-hour trading volume ratio of ETH contracts to spot is 13.8.
Bijie data: Over the most recent 4 full hours, ETHUSDT perpetual contract trading volume was 13.8 times spot trading volume. Compared with the same-caliber snapshot 24 hours earlier, it fell by 4.1701; compared with the same-caliber snapshot 7 days earlier, it fell by 3.5531.
US equity options open interest stands at 409,659,770 contracts.
BiJie.com US stock data: US single-stock options open interest stands at 409,659,770 contracts, of which 251,014,115 are calls and 158,645,655 are puts.
China Telecom's Institute of Artificial Intelligence has incubated embodied AI company Gamma Intelligence in Shanghai.
CoinWorld news: Gamma Robotics, an embodied intelligence company incubated by the China Telecom Artificial Intelligence Research Institute (TeleAI), has been registered and established in Xuhui District, Shanghai, and has moved into the Model Speed Space. The company is an independent market-oriented entity invested by China Telecom Group and incubated by TeleAI, and will jointly build a humanoid robot laboratory with TeleAI. Professor Li Xuelong, CTO and Chief Scientist of China Telecom Group, will serve as scientific advisor to Gamma Robotics, and Bai Chenjia will serve as founder and CEO.
Rubio: Without U.S. support, Ukraine "would cease to exist"
US Secretary of State Rubio defended the Trump administration's support for Ukraine, saying that without US support, Ukraine "would cease to exist" as a country. He made the remarks in response to a question about a Wall Street Journal report that SpaceX CEO Elon Musk ordered a slowdown in the operation of the Starlink satellite system, which has been helping Ukraine defend against Russian airstrikes. Rubio said he did not know whether the president had been informed of the matter in advance; he also noted that, in any case, the United States cannot control how a private company handles its products. Rubio disclosed that US special envoy Witkoff will hold talks with the Russian side in St. Petersburg, which will be "a very tough negotiation." He said the current talks focus on the fate of the Donbas region in eastern Ukraine, and added that the two sides have put forward some "creative ideas" to bridge differences.
Samsung Electronics and SK Hynix upgrade their Chinese factories to meet AI demand.
Reuters reports that Samsung Electronics and SK Hynix are upgrading their factories in China to produce more advanced memory chips, aiming to withstand pressure from rapidly growing Chinese competitors and meet massive AI demand.